Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
copper(II)-tolfenamic acid complex
- Development stage
- Preclinical
- Lead developer
- University of North Texas Health Science Center
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Copper(II)-tolfenamic acid complex (Cu-TA) is a research-stage small molecule metallodrug formed by the coordination of copper(II) ions with the non-steroidal anti-inflammatory drug (NSAID) tolfenamic acid. It is primarily being investigated for its anti-cancer properties across various malignancies, including pancreatic cancer, Ewing sarcoma, and glioblastoma. The complex exhibits enhanced therapeutic efficacy compared to tolfenamic acid alone, likely due to its ability to downregulate the anti-apoptotic protein survivin and its transcription factors, Specificity protein 1 (Sp1) and Sp3, through post-translational degradation. Additionally, Cu-TA demonstrates significant antioxidant activity and the ability to induce cell cycle arrest and apoptosis in cancer cells.
- Other names
- copper(II) tolfenamateCu(II)-tolfenamic acid complex
02
Targets
SP3 (Transcription factor Sp3)BIRC5 (Survivin)SP1 (Transcription factor Sp1)
Beyond the preview
Go deeper on copper(II)-tolfenamic acid complex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on copper(II)-tolfenamic acid complex.